Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain 
of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of 
PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent 
tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin 
chemotherapy significantly improved overall survival, leading to FDA approval.